A genetic variant, x285k in hoxb13, is associated with risk of aggressive prostate cancer in men of african ancestry
AssigneeThe Johns Hopkins University
InventorsWilliam Brewster Isaacs, Jun Luo, Mayuko Kanayama
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for treating patients having a HOXB13 genetic variant. In a specific embodiment, a method for identifying a subject as having an increased risk of prostate cancer (PCa) comprises the step of detecting single nucleotide polymorphism rs77179853 in DNA isolated from the subject, wherein the presence of the rs77179853 SNP identifies the subject as having an increased risk of aggressive prostate cancer.
Claims22
A method for identifying a subject as having an increased risk of prostate cancer (PCa) comprising the step of detecting single nucleotide polymorphism rs77179853 in DNA isolated from the subject, wherein the presence of the rs77179853 SNP identifies the subject as having an increased risk of aggressive prostate cancer.
A method for determining whether a subject will not respond to androgen or androgen receptor-directed therapies comprising the step of detecting single nucleotide polymorphism rs77179853 in DNA isolated from the subject, wherein the presence of the rs77179853 SNP indicates that the subject will not respond, or have a poor outcome, to androgen or androgen receptor-directed therapies.
A method for treating a subject at risk of or having PCa comprising the steps of:
- (a) detecting single nucleotide polymorphism rs77179853 in DNA isolated from the subject, wherein the presence of the rs77179853 SNP identifies the subject as having poor response to androgen or androgen receptor-directed therapies;
- and
- (b) administering a non-androgen or non-androgen receptor therapies to treate the subject.
A method for identifying a subject as having an increased risk of prostate cancer (PCa) comprising the step of detecting a protein comprising SEQ ID NO:13 or a nucleic acid encoding SEQ ID NO:
- 13 in a sample obtained from the subject, wherein the presence of the protein comprising SEQ ID NO:
- 13 or the nucleic acid encoding SEQ ID NO:13 identifies the subject as having an increased risk of aggressive prostate cancer.
A method for determining whether a subject will not respond to androgen therapy comprising the step of detecting a protein comprising SEQ ID NO:13 or a nucleic acid encoding SEQ ID NO:
- 13 in a sample obtained from the subject, wherein the presence of the protein comprising SEQ ID NO:
- 13 or the nucleic acid encoding SEQ ID NO:13 indicates that the subject will not respond to androgen therapy.
Dependencies are inferred from the claim text.